Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Autonomix MedicalAMIX -11.27%15 3-Year FCF Growth Rate is 1.20% as of Jun. 2026, which is at its 10-year median of 1.20. GuruFocus rates AMIX with a GF Score™ of 15/100. The stock has 2 warning signs investors should review. Among 585 Medical Devices & Instruments companies, Autonomix Medical ranks worse than 67.35% on this metric.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 1.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 4 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Autonomix Medical was 1.20% per year. The lowest was 1.20% per year. And the median was 1.20% per year.
Autonomix Medical (NAS:AMIX) 3-Year FCF Growth Rate Explanation
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Autonomix Medical 3-Year FCF Growth Rate Related Terms
AMIX vs AEMD, NUMD, ESMC: 3-Year FCF Growth Rate Comparison
For the Medical Devices subindustry, Autonomix Medical's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Autonomix Medical 3-Year FCF Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Autonomix Medical's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Autonomix Medical's 3-Year FCF Growth Rate falls into.
Autonomix Medical 3-Year FCF Growth Rate Calculation
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
Autonomix Medical (AMIX) has a 3-Year FCF Growth Rate of 1.20% as of Jun. 2026. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Autonomix Medical and its competitors. This is near median its historical median of 1.20. Over the past decade, Autonomix Medical's 3-Year FCF Growth Rate has ranged from 1.20 to 1.20. According to the industry distribution chart, Autonomix Medical ranks #394 out of 585 companies in the Medical Devices & Instruments industry, placing it in the top 67.4%.
Is Autonomix Medical's 3-Year FCF Growth Rate too high?
Autonomix Medical's current 3-Year FCF Growth Rate of 1.20% is near median its 10-year median of 1.20. Over the past 10 years, this metric has ranged from a low of 1.20 to a high of 1.20. The Medical Devices & Instruments industry median 3-Year FCF Growth Rate is 18.00. Autonomix Medical's value of 1.20% is 93.3% below this industry median. Based on the distribution chart, Autonomix Medical ranks #394 out of 585 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Autonomix Medical has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Autonomix Medical's 3-Year FCF Growth Rate compare to AEMD and NUMD?
According to the Medical Devices & Instruments industry distribution chart, Autonomix Medical ranks #394 out of 585 companies for 3-Year FCF Growth Rate. This places Autonomix Medical in the lower half of its industry. The industry median 3-Year FCF Growth Rate is 18.00. Autonomix Medical's value of 1.20% is 93.3% below this benchmark. Historically, Autonomix Medical's own 3-Year FCF Growth Rate has ranged from 1.20 to 1.20 over the past decade. While the company's 10-year median is 1.20 vs. the industry median of 18.00, Autonomix Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Medical Devices & Instruments company?
The median 3-Year FCF Growth Rate among Medical Devices & Instruments companies is 18.00, based on 585 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Autonomix Medical's current 3-Year FCF Growth Rate of 1.20% is 93.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Autonomix Medical and its competitors. For the Medical Devices & Instruments industry, the median 3-Year FCF Growth Rate is 18.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Autonomix Medical's current 3-Year FCF Growth Rate is 1.20%, which is near median its own 10-year median of 1.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Autonomix Medical stock overvalued right now?
Autonomix Medical (AMIX) has a current 3-Year FCF Growth Rate of 1.20%. The current 3-Year FCF Growth Rate is 1.20%, which is near median its 10-year median of 1.20 and 93.3% below the Medical Devices & Instruments industry median of 18.00. Autonomix Medical's overall GF Score™ is 15/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For Autonomix Medical (AMIX), the current 3-Year FCF Growth Rate is 1.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Autonomix Medical Inc is a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Its platform is designed to integrate high-sensitivity neural signal detection with targeted radiofrequency (RF) ablation, enabling a sense, treat, verify approach for nerve-targeted therapies. The Company operates in one reportable segment, which is advancing the development of technologies for sensing and treating disorders relating to the nervous system. It is initially focused on developing the technology for patients with pancreatic cancer and believes the technology has the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease, and other nerve-related disorders.
15GF Score
Get the complete analysis for AMIX
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMIX has been successfully added to your 
